Individuals afflicted with blood cancer face an elevated risk of infections, typically due to their low antibody levels, a phenomenon known as secondary hypogammaglobulinemia. This condition arises from interference with antibody production, leaving the body exposed to potential infections. Such interference can be traced back to certain hematological malignancies which infiltrate the bone marrow where B cells, responsible for antibody production, are manufactured.Â
As if this isn’t daunting enough, certain cancer treatments can further suppress B cell function, contributing to low levels of immunoglobulin, and therefore, heightened infection susceptibility. Consequently, these patients grapple with a dual threat: the cancer itself coupled with an upsurge in infection risk due to hypogammaglobulinemia. To avert infections, physicians oftentimes employ either immunoglobulin (Ig) replacement therapy or preventative antibiotics. Despite their widespread use, a direct comparison of these treatments’ efficacy had not previously been undertaken.Â
Addressing this research gap, Professor Zoe McQuilten, a consultant hematologist at Monash Health, Australia, and her team conducted a study encompassing seven hospitals across New Zealand and Australia. Their investigation involved blood cancer patients plagued by recurrent or severe infections or spanning extremely low levels of immunoglobulin G (below 4 g/L). Participants were randomly allocated either monthly intravenous immunoglobulin replacement therapy or daily preventative antibiotics for one year.Â
The study’s findings signified similar survival rates and periods until the first major infection occurrence, as well as reported quality of life across both therapy groups, thereby demonstrating that these treatments could be equally potent in preventing infections. This pioneering study, through direct comparison of two common preventive therapies, significantly advances our understanding of their comparative efficacy in infection prevention, setting a course for more comprehensive evaluations aiming at optimizing infection prevention strategies for blood cancer patients.
Source: https://healthtree.org/myeloma/community/articles/immunoglobulin-antibiotics-blood-cancer-infections